CGAS Gene

Introduction

Pathway Diagram

flowchart TD
    CGAS["cGAS<br/>(Cyclic GMP-AMP Synthase)"]
    MT_DNA["Mitochondrial DNA<br/>(Damage/Release)"]
    CGAMP["cGAMP<br/>(Second Messenger)"]
    STING["STING<br/>(Stimulator of IFN Genes)"]
    INFLAMMATION["Inflammatory<br/>Response"]
    NEUROINFLAMMATION["Neuroinflammation"]
    ALS["Amyotrophic Lateral<br/>Sclerosis (ALS)"]
    MS["Multiple Sclerosis<br/>(MS)"]
    ALZHEIMER["Alzheimer's<br/>Disease"]
    TAUOPATHY["Tauopathy"]
    NEURODEGENERATION["Neurodegeneration"]
    AGING["Cellular<br/>Aging"]
    SENESCENCE["Cellular<br/>Senescence"]
    AUTOIMMUNE["Autoimmune<br/>Response"]
    FIBROSIS["Tissue<br/>Fibrosis"]

    MT_DNA -->|"releases"| CGAS
    CGAS -->|"catalyzes"| CGAMP
    CGAMP -->|"activates"| STING
    STING -->|"triggers"| INFLAMMATION
    CGAS -->|"activates"| INFLAMMATION
    INFLAMMATION -->|"contributes to"| NEUROINFLAMMATION
    NEUROINFLAMMATION -->|"drives"| NEURODEGENERATION
    CGAS -->|"associated with"| ALS
    CGAS -->|"activates"| ALS
    CGAS -->|"complex role"| MS
    CGAS -->|"associated with"| ALZHEIMER
    CGAS -->|"associated with"| TAUOPATHY
    CGAS -->|"activates"| AGING
    AGING -->|"leads to"| SENESCENCE
    CGAS -->|"associated with"| SENESCENCE
    CGAS -->|"activates"| AUTOIMMUNE
    CGAS -->|"regulates"| FIBROSIS

    style CGAS fill:#006494
    style INFLAMMATION fill:#ef5350
    style NEUROINFLAMMATION fill:#ef5350
    style ALS fill:#5d4400
    style MS fill:#5d4400
    style ALZHEIMER fill:#5d4400
    style TAUOPATHY fill:#5d4400
    style NEURODEGENERATION fill:#5d4400
    style MT_DNA fill:#ef5350
    style STING fill:#4a1a6b
    style CGAMP fill:#4a1a6b
    style AGING fill:#ef5350
    style SENESCENCE fill:#ef5350
    style AUTOIMMUNE fill:#ef5350
    style FIBROSIS fill:#ef5350

The CGAS (Cyclic GMP-AMP Synthase) gene encodes a crucial DNA sensor protein that plays a central role in the innate immune response to cytosolic DNA. Originally discovered in the context of antiviral immunity, cGAS has emerged as a critical player in the pathogenesis of Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders. This gene provides a molecular link between genomic instability, mitochondrial dysfunction, and chronic neuroinflammation that characterizes these devastating conditions

Official Symbol: CGAS Official Full Name: Cyclic GMP-AMP Synthase Previous Names: MB21D1, cGAS Location: Chromosome 6q15 Gene ID: 115004 Ensemble ID: ENSG00000154122 OMIM ID: 617561

Gene Structure and Organization

The CGAS gene spans approximately 24 kilobases and consists of 8 exons encoding a protein of 522 amino acids with a molecular weight of approximately 57 kDa. The gene structure has been conserved throughout evolution, reflecting its fundamental importance in cellular immunity^{2Structure of human cGAS reveals a conserved catalytic corePMID 24316788Open reference}.

Genomic Organization:

• Exon 1: Encodes the N-terminal structured domain

• Exons 2-4: Encode the central regulatory region

• Exons 5-8: Encode the C-terminal nucleotidyltransferase domain

The promoter region contains interferon-stimulated response elements (ISRE), allowing for transcriptional upregulation in response to type I interferons. This creates a positive feedback loop that can amplify cGAS expression during chronic inflammation.

Protein Structure and Function

cGAS adopts a unique fold distinct from other nucleotidyltransferases, consisting of two primary structural domains^{3Structural mechanism of cytosolic DNA sensing by cGASPMID 23829405Open reference4Structure of the human cGAS-DNA complex reveals the basis for immune activationPMID 24165430Open reference}:

N-Terminal Domain (Residues 1-160)

The N-terminal region contains:

• Multiple serine/threonine residues subject to phosphorylation

• A zinc ribbon motif involved in DNA binding

• Regulatory sequences controlling enzymatic activity

• An autoinhibitory element that maintains basal inactivity

C-Terminal Nucleotidyltransferase Domain (Residues 161-522)

This domain contains:

• Catalytic core with conserved Asp-Asp-Glu (DDE) motif

• DNA-binding surfaces on the outer face

• STING interaction interface

• ATP/GTP binding pocket

• Zinc-dependent DNA binding module

Catalytic Mechanism

cGAS catalyzes the synthesis of cyclic GMP-AMP (cGAMP) from ATP and GTP through a two-step reaction:

1. First step: ATP + GTP → pppGpG (linear dinucleotide)

2. Second step: pppGpG → cGAMP (cyclic product)

The resulting 2’,3’-cGAMP contains mixed phosphodiester bonds (one 3’,5’ and one 2’,5’ linkage), distinguishing it from other cyclic nucleotides. This unique structure enables high-affinity binding to STING with dissociation constants in the nanomolar range^{5cGAS produces a 2',3'-cGAMP second messenger that enables STING to bind and activate transcriptionPMID 23345441Open reference}.

Molecular Mechanisms of Activation

DNA Binding and Oligomerization

cGAS binds double-stranded DNA (dsDNA) in a sequence-independent manner, with binding affinity enhanced by DNA length and higher-order structure. Key activation steps include^{6cGAS in cytosolic DNA sensing and beyondPMID 31125883Open reference}:

1. DNA binding: dsDNA binds to the DNA-binding surfaces on cGAS

2. Conformational change: DNA binding induces structural rearrangement

3. Oligomerization: cGAS molecules form liquid-like condensates on DNA

4. Catalytic activation: Oligomerization enables trans-autocatalysis

Liquid-Liquid Phase Separation

cGAS undergoes liquid-liquid phase separation (LLPS) upon DNA binding, forming biomolecular condensates that concentrate cGAS molecules and enhance catalytic activity. This process is mediated by:

• Multivalent interactions between cGAS and DNA

• π-π stacking interactions between aromatic residues

• Electrostatic interactions with the DNA phosphate backbone

STING Activation and Downstream Signaling

Activated cGAS produces cGAMP, which binds to STING (encoded by TMEM173) in the endoplasmic reticulum. This triggers:

1. STING conformational change

2. STING translocation to the Golgi apparatus

3. TBK1 recruitment and activation

4. IRF3 phosphorylation and nuclear translocation

5. Type I interferon (IFN-α/β) transcription

6. Inflammatory cytokine production

Expression Pattern and Cellular Distribution

Tissue Distribution

cGAS is ubiquitously expressed across tissues, with highest levels in immune organs:

Cellular Expression in the Brain

Within the central nervous system, cGAS is expressed in^{7DNA sensing by the cGAS-STING pathway in innate immunityPMID 31125019Open reference}:

Neurons:

• Constitutively expressed in most neuronal populations

• Particularly high in cortical and hippocampal neurons

• Upregulated during neurodegeneration

Glial Cells:

• Astrocytes: Moderate constitutive expression

• Microglia: High expression, increases with activation

• Oligodendrocytes: Lower baseline expression

Subcellular Localization

cGAS localizes primarily to the cytosol, but can also be found:

• Associated with nuclear envelope (proximity to genomic DNA)

• In mitochondrial periphery (mitochondrial DNA sensing)

• In stress granules during cellular stress

Role in Neurodegenerative Diseases

Alzheimer’s Disease

cGAS-STING pathway activation is a hallmark of AD pathophysiology^{8Activation of cGAS-STING pathway in Alzheimer's diseasePMID 35892789Open reference9cGAS-STING regulates neuroinflammation in Alzheimer's diseasePMID 35921456Open reference}:

Evidence:

• Elevated cGAS expression in AD brain tissue

• Increased cGAMP levels in AD patient cerebrospinal fluid

• cGAS colocalization with amyloid plaques and neurofibrillary tangles

• Type I interferon signature in AD brain transcriptomes

• cGAS activation in microglia surrounding amyloid deposits

Mechanisms:

• Amyloid-β (Aβ) deposition triggers mitochondrial dysfunction

• Mitochondrial DNA released into cytosol activates cGAS

• Nuclear envelope dysfunction allows genomic DNA leakage

• DNA damage accumulation from oxidative stress

• Microglial cGAS activated by phagocytosed debris

Consequences:

• Chronic type I interferon response

• Enhanced microglial activation and cytokine release

• Synaptic pruning acceleration

• Neuronal dysfunction and death

Parkinson’s Disease

The cGAS-STING pathway contributes to PD through multiple mechanisms^{10The cGAS-STING pathway in Parkinson's diseasePMID 35081756Open reference}:

Evidence:

• Elevated STING expression in dopaminergic neurons

• cGAS activation in PD substantia nigra

• Increased cGAMP in PD patient CSF

• IFN-responsive genes upregulated in PD brain

Mechanisms:

• Mitochondrial dysfunction in dopaminergic neurons leads to mtDNA release

• α-Synuclein aggregation induces DNA damage

• Environmental toxins (MPTP, rotenone) cause DNA damage

• Lysosomal dysfunction promotes nuclear DNA leakage

Consequences:

• Neuroinflammation in substantia nigra

• Accelerated dopaminergic neuron loss

• Enhanced α-synuclein aggregation through impaired autophagy

Amyotrophic Lateral Sclerosis

cGAS-STING activation in ALS involves^{2Structure of human cGAS reveals a conserved catalytic corePMID 24316788Open reference}0:

Evidence:

• STING upregulation in motor neurons

• cGAS activation in astrocytes and microglia

• IFN signature in ALS spinal cord

Mechanisms:

• TDP-43 pathology triggers DNA damage

• Mitochondrial dysfunction is prevalent

• FUS mutations cause DNA repair impairment

• Oxidative stress contributes to DNA damage

Consequences:

• Motor neuron inflammation

• Glial activation and toxicity

• Accelerated disease progression

Other Neurodegenerative Conditions

cGAS-STING involvement has been reported in:

Multiple Sclerosis:

• Demyelination triggers cGAS activation

• Oligodendrocyte vulnerability

Huntington’s Disease:

• Mutant huntingtin causes DNA damage

• cGAS contributes to neuroinflammation

Frontotemporal Dementia:

• TDP-43 pathology linked to cGAS

• Similar mechanisms to ALS

Genetic Variants and Disease Risk

Known CGAS Variants

Several CGAS variants have been associated with disease:

GWAS Findings

While no common CGAS variants have reached genome-wide significance in neurodegenerative diseases, pathway analyses suggest involvement of cGAS-STING pathway genes in AD and PD genetic risk scores.

Therapeutic Implications

cGAS Inhibitors in Development

Several cGAS targeting approaches are under development^{2Structure of human cGAS reveals a conserved catalytic corePMID 24316788Open reference}1^{2Structure of human cGAS reveals a conserved catalytic corePMID 24316788Open reference}2:

Direct cGAS Inhibitors:

• RU.521: Selective cGAS inhibitor, reduces tau-induced inflammation^{2Structure of human cGAS reveals a conserved catalytic corePMID 24316788Open reference}3

• Compound 3: Blocks cGAS catalytic activity

• PF-069: Brain-penetrant cGAS inhibitor

Mechanism of Action:

• Competitive inhibition of DNA binding

• Allosteric modulation of catalytic site

• Prevention of phase separation

STING Inhibitors (Downstream Target)

• H-151: Covalent STING antagonist, blocks palmitoylation

• C-176/C-178: STING trafficking inhibitors

STING inhibition shows benefit in AD models: Mathavarajan et al. (2024) demonstrated that STING inhibition reduces neuroinflammation and improves cognitive function in AD mouse models^{2Structure of human cGAS reveals a conserved catalytic corePMID 24316788Open reference}4.

Repurposing Opportunities

Existing drugs with cGAS-STING effects:

• Hydroxychloroquine: Blocks STING activation

• Metformin: Modulates mitochondrial cGAS signaling

• Aspirin: Inhibits NF-κB downstream of STING

Gene Therapy Approaches

• AAV-mediated cGAS knockdown

• CRISPR-based cGAS inactivation

• Soluble STING decoy proteins

Animal Models

Genetic Knockout Models

cGAS Knockout Mice (cGAS-/-):

• Viable and fertile

• Defective in cytosolic DNA sensing

• Protected from DNA damage-induced senescence

• Reduced neuroinflammation in disease models

STING Knockout Mice (STING-/-):

• Impaired type I interferon response

• Protected from neuroinflammation

• Used to confirm cGAS-STING pathway involvement

Disease Models

• 5xFAD mice: Show elevated cGAS-STING activation

• MPTP model: cGAS activation in substantia nigra

• Tauopathy models: cGAS responds to pathological tau

Biomarker Potential

cGAMP as Biomarker

cGAMP serves as a potential biomarker for cGAS-STING activation:

• Elevated in AD and PD cerebrospinal fluid

• Correlates with disease severity

• Can be measured by mass spectrometry

Interferon Signature

Type I interferon-stimulated genes (ISGs) serve as downstream markers:

• Elevated in neurodegenerative disease brain

• Detectable in peripheral blood

• Potential for disease monitoring

Future Directions

Research Priorities

1. Cell-type specific functions: Determine neuronal vs. glial cGAS contributions

2. Biomarker development: Validate cGAMP and ISG signatures

3. Therapeutic optimization: Develop brain-penetrant inhibitors

4. Clinical translation: Move cGAS-STING inhibitors to clinical trials

Outstanding Questions

• What initiates cGAS activation in sporadic neurodegeneration?

• Can cGAS inhibition provide neuroprotection in human patients?

• What determines the cell-type specific pattern of cGAS-STING activation?

• How does cGAS-STING interact with other inflammatory pathways?

Cross-Links to Related Pages

• STING Gene - Downstream partner of cGAS

• TBK1 Gene - Key signaling kinase

• IRF3 Gene - Transcription factor

• cGAS-STING Pathway in Neurodegeneration

• cGAS-STING Signaling in Parkinson’s Disease

• Mitochondrial Dysfunction in Neurodegeneration

• Neuroinflammation

• Cellular Senescence

External Links

• NCBI Gene: CGAS

• UniProt: cGAS

• OMIM: CGAS

• Ensembl: CGAS

• PubMed Central - cGAS-STING in AD

• PubMed Central - cGAS-STING in PD